How resources are being diverted to COVID-19, and how they have been affecting Tuberculosis resources, knowing when to suspect and diagnose active Tuberculosis and how to manage the patient
COVID is an exceptional disease and was at its deadliest this year, causing more deaths in Australia between June and August 2022 than at any other time.
In this Product Explainer, Infectious Disease Physician and Clinical Microbiologist A/Prof Paul Griffin explains Australia’s first and only cell-based influenza vaccine, as well as the differences between influenza vaccines and why this is important to understand in order to better inform patients of the choices available (5 mins).
Despite a panoramic study suggesting a lower effect, Lagevrio has a useful impact on hospitalisations, deaths and shorter recovery time. Additionally COVID trials becoming more difficult to run because so many people have either been vaccinated and / or exposed
The elimination of isolation periods and mask mandates, and an update on the vaccination landscape, including recently approved jabs, the bivalent vaccine, and vaccination for children
Almost three years into the pandemic, the widespread uptake of vaccines in Australia, together with the large rate of infection from the Omicron variant has created very good population immunity, according to Professor Kristine Macartney from the National Centre for Immunisation Research.
Navigating interactions... it’s easier than it first looks, and how antivirals are an important part of the management strategy to reduce the chances of severe illness and hospital admissions